New York, NY — October 16, 2025 — Leads & Copy — Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) hosted an R&D Day in New York City, presenting the full Phase 1 dataset and outlining the pivotal Phase 2 trial design and commercial opportunity for lasme-cel in r/r B-ALL.
The event featured presentations from the company’s leadership team and key opinion leaders.
A replay will be available on the Cellectis website after the event.
Cellectis is a clinical-stage biotechnology company utilizing gene-editing to develop cell and gene therapies, pioneering off-the-shelf CAR T-cells for cancer treatment. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC.
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Source: Cellectis
